Fluticasone propionate compared with budesonide: A double-blind trial in asthmatic children using powder devices at a dosage of 400 μg·day-1

European Respiratory Journal

Volumn 9, Issue 11, 1996, Pages 2263-2272

  Hoekx, J C M ^a   Hedlin, G ^b   Pedersen, W ^c   Sorva, R ^d   Hollingworth, K ^e   Efthimiou, J ^e  

^a GROENE HART HOSPITAL   (Netherlands)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Paediatric Dept   (Denmark)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Asthma; Budesonide; Fluticasone propionate; Paediatric; Powder device

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; METHYLXANTHINE DERIVATIVE;

AEROSOL; ARTICLE; ASTHMA; CHILD; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN ALLERGY;

ADMINISTRATION, TOPICAL; ADOLESCENT; AEROSOLS; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BONE AND BONES; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROXYPROLINE; MALE; NEBULIZERS AND VAPORIZERS; OSTEOCALCIN; PATIENT SATISFACTION; PEAK EXPIRATORY FLOW RATE; PEPTIDE FRAGMENTS; PREGNENEDIONES; PROCOLLAGEN; QUESTIONNAIRES;

EID: 0029860552     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.96.09112263     Document Type: Article

References (45)

1. British Thoracic Society. Guidelines for management of asthma in adults. I. Chronic persistent asthma. BMJ 1990; 301: 651-653.
2. National Heart, Lung and Blood Institute, National Institute of Health, Bethesda, Maryland, USA. International consensus report on diagnosis and treatment of asthma. Eur Respir J 1992; 5: 601-641.
3. Warner JO, Neijens HJ, Landau LI, et al. Asthma: a follow-up statement from an international paediatric asthma consensus group. Arch Dis Child 1992; 67: 240-248.
4. Molema J, Van Herwaarden CLA, Folgering HTM. Effects of long-term treatment with inhaled cromoglycate and budesonide on bronchial hyperresponsiveness in patients with allergic asthma. Eur Respir J 1989; 2: 308-316.
5. Geddes DM. Inhaled corticosteroids: benefits and risks. Thorax 1992; 47: 404-407.
6. Warner JO, Reiser J. Inhaled glucocorticoids in childhood asthma. In: Godfrey S, eds. Glucocorticosteroids in Childhood Aslhma, Exerpta Medica, Amsterdam, 1987; pp. 78-84.
7. Springer C, Avital A, Maayan CH, et al. Comparison of budesonide and beclomethasone dipropionate for treatment of asthma. Arch Dis Child 1987; 62(8): 815-819.
8. Baran D. A comparison of inhaled budesonide and beclomethasone dipropionate in childhood asthma. Br J Dis Chest 1987; 81(2): 170-175.
9. Brogden RN, McTavish D. Budesonide an updated review of its pharmacological properties and therapeutic efficacy in asthma and rhinitis. Drugs 1992; 44(3): 375-407.
10. Pedersen S, Fugslang G. Urine cortisol excretion in children treated with high doses of inhaled corticosteroids: a comparison of budesonide and beclomethasone. Eur Respir J 1988; 1: 433-435.
11. Field HV, Jenkinson PMA, Frame MH, et al. Asthma treatment with a new corticosteroid aerosol budesonide, administered twice daily by spacer inhaler. Arch Dis Child 1982; 57(11): 864-866.
12. Holliday SM, Faulds D, Sorkin EM. Inhaled fluticasone propionate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma. Drugs 1994; 47: 318-331.
13. Phillipps GH. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med 1990; 84 (suppl. A): 19-23.
14. Ryerfeldt Å, Andersson P, Edsbäcker S, et al. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982; 63 (suppl. 122): 86-95.
15. Harding SM. The human pharmacology of fluticasone propionate. Respir Med 1990; 84 (suppl. A): 25-29.
16. -1 in mild and moderate asthma. Arch Dis Child 1993; 69: 206-211.
17. Lundback B, Dahl R, De Jonghe M, Hyldebrandt N, Yalta R, Payne SL. A comparison of fluticasone propionate when delivered by either the metered-dose inhaler or the Diskhaler in the treatment of mild-to-moderate asthma. Eur J Clin Res 1994; 5: 11-19.
18. -1) administered by pressurized inhaler. Respir Med 1993; 87: 609-620.
19. Agertoft L, Pedersen S. Importance of inhalation device on the effect of budesonide. Arch Dis Child 1993; 69: 130-133.
20. White FA, Toogood JH, Baskerville J, Hodsman A. A comparison of the efficacy and systemic effects of budesonide administered as an aerosol via metered-dose inhaler + Nebuhaler and as a dry powder via Turbuhaler [Abstract]. J Allergy Clin Immunol 1995; 95 (No. 1, part 2): 688.
21. Selroos O, Holme M. Effect of a Volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. Thorax 1991; 46: 891-894.
22. Brown PH, Lenney J, Armstrong S, et al. Breath-actuated inhalers in chronic asthma: comparison of Diskhaler and Turbohaler for delivery of beta-agonists. Eur Respir J 1992; 5: 1143-1145.
23. Petrie GR, Choo-Kang YFS, Clark RA, et al. An assessment of the acceptability of two breath-actuated corticosteroid inhalers, comparison of Turbohaler and Diskhaler. Drug Invest 1990; 2(2): 129-131.
24. Harvey J, Williams JG. Randomised, cross-over comparison of five inhaler systems for bronchodilator therapy. Br J Clin Pract 1992; 46: 249-251.
25. Connolly A. A Comparison of fluticasone propionate, 100 μg twice daily, with budesonide, 200 μg twice daily via their respective powder devices in the treatment of mild asthma. Eur J Clin Res 1995; 7: 15-29.
26. Langdon CG, Capsey LJ. Fluticasone propionate and budesonide in adult asthmatics: a comparison using dry-powder inhaler devices. Br J Clin Res 1994; 5: 85-99.
27. Ayres JG, Bateman ED, Luundback B, Harris TAJ. High dose fluticasone, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. Eur Respir J 1995; 8: 579-586.
28. Williams J. Efficacy and use of the fluticasone propionate multi-dose powder inhaler compared with the budesonide reservoir powder device in asthmatic children. Eur Respir J 1995; 8 (suppl. 19): P2313.
29. Polgar G, Promhadhat V. Pulmonary function testing in children: techniques and standards. London, W.P. Saunders, 1971.
30. Conover JW. In: Practical Nonparametric Statistics. 2nd edn. New York, John Wiley and Sons, 1980; pp. 223-225.
31. Lehman EL. In: Nonparametrics: Statistical Methods Based on Ranks. San Francisco, Holden-Day Inc., 1995; p. 135.
32. Lenney W, Wells NEJ, O'Neill BA. The burden of paediatric asthma. Eur Resp Rev 1994; 4(18): 49-62.
33. Juniper EF, Johnston PR, Borkhoff CM, Guyatt GH, Boulet LP, Haukioja A. Quality of life in asthma: Comparison of salmeterol and salbutamol. Am J Respir Crit Care 1995; 151: 66-70.
34. Nicolaizik WH, Marchant JL, Preece MA, Warner JO. Endocrine and lung function in asthmatic children on inhaled corticosteroids. Am J Respir Crit Care Med 1994; 150: 624-628.
35. Priftis K, Milner AD, Conway E, Honour JW. Adrenal function in asthma. Arch Dis Child 1990; 65: 838-840.
36. Bisgaard H, Nielsen MD, Anderson B, et al. Adrenal function in children with bronchial asthma treated with beclomethasone dipropionate or budesonide. J Allergy Clin Immunol 1988; 81: 1088-1095.
37. Pedersen S, Fuglsang G. Urine cortisol excretion in children treated with high doses of inhaled corticosteroids: a comparison of budesonide and beclomethasone Eur Respir J 1988; 1: 433-435.
38. Mackenzie CA, Weinberg EG, Tabachnik E, Taylor M, Havnen J, Crescenzi K. A placebo-controlled trial of fluticasone propionate in asthmatic children. Eur J Pediatr 1993; 152: 856-860.
39. Mackenzie CA, Tsanakas J, Tabachnik E, et al. An open study to assess the long-term safety of fluticasone propionate in asthmatic children. Br J Clin Prac 1994; 48: 15-18.
40. Sorva R, Turpeinen M, Juntunen-Backman K, Karonen S, Sorva A. Effects of inhaled budesonide on serum markers of bone metabolism in children with asthma. J Allergy Clin Immunol 1992; 90: 808-815.
41. Priftis K, Voskaki I, Papadimitriou A, et al. Effects of long term treatment with inhaled steroids on bone metabolism in asthmatic children. Eur Respir J 1994; 7 (suppl. 18): 285.
42. Doull JM, White M, Freezer NJ, Holgate ST. Markers of bone metabolism in asthmatic children receiving inhaled corticosteroids. Eur Respir J 1994; 7 (suppl. 18): 285.
43. Konig P, Hillman L, Cervantes C, et al. Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate. J Pediatr 1993; 122: 219-226.
44. Wolthers O, Pedersen S. Measures of systemic activty of inhaled glucocorticoids in children: a comparison of urine cortisol and knemometry. Respir Med 1995; 89: 347-349.
45. Agertoft L, Pedersen S. Short-term lower leg growth in children during treatment with fluticasone propionate and budesonide: a dose response study. Am J Respir Crit Care Med 1995; 151(4): A150.